Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 46,375

Document Document Title
WO/2014/075203
The invention relates to a novel pharmaceutical formulation comprising polymer nanoparticles of the biodegradable and biocompatible polymer poly (lactic-glycolic) acid (PLGA), loaded with the drug pentoxifylline, the method for the synth...  
WO/2014/076702
A method of treating a disease selected from the group consisting of emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia, a neurodegenerative disorder, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischem...  
WO/2014/078314
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In...  
WO/2014/075570
Disclosed are a beautyberry total glycosides extract, a preparation method thereof and the use in preparing drugs for treating neurodegenerative diseases or skin diseases. The extract is prepared from the leaves of Callicarpa cathayana o...  
WO/2014/075387
Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in t...  
WO/2014/078454
Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of...  
WO/2014/077401
 Provided is a compound that has cholinergic muscarinic M1 receptor positive allosteric modulator activity and that is useful in the prevention and treatment of conditions such as Alzheimer's disease, schizophrenia, pain, and sleep dis...  
WO/2014/078645
Disclosed herein are heterocyclic compounds containing thiadiazole and/or pyridazine rings, as well as pharmaceutical preparations thereof. The compounds herein are further made known to be useful as glutaminase inhibitors with potential...  
WO/2014/076170
The present invention relates to new substituted pyrazolo[3,4- d]pyrimidine compounds of general formula (I) having a great affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof,...  
WO/2014/076235
The present invention relates to a composition for treating Fragile X syndrome in a subject in need thereof, wherein said composition comprises an effective amount of a modulator of a chloride transporter.  
WO/2014/078394
The current invention offers a method of treatment of aggression in a human subject suffering from ADHD, comprising: (a) determining the weight of the human subject; (b) calculating a dose of molindone such to achieve a plasma concentrat...  
WO/2014/078372
Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH-C...  
WO/2014/076643
A compound particularly for treating depression and anxiety, characterized in that it comprises the combination of at least 11 -keto-beta- boswellic acid (KBA) and acetyl-11-keto-beta-boswellic acid (AKBA). The patent also relates to the...  
WO/2014/075629
A method of extracting neural stem cells from a living subject, comprising the steps of introducing magnetic nanoparticles into the subject, targeting the neural stem cells with the magnetic nanoparticles to form magnetic nanoparticle-ta...  
WO/2014/075146
The present invention relates to novel macrocyclic compounds of Formula I and their use as novel therapeutic agents for example as novel compounds used in methods of preventing and/or treating a disease, condition or state in a subject a...  
WO/2014/074381
The subject invention provides a Laquinimod amine salt, which is laquinimod meglumine, laquinimod choline hydroxide, laquinimod L-lysine or laquinimod monoethanolamine.  
WO/2014/073889
The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperatu...  
WO/2014/071507
The disclosure provides compositions containing preparations from plants of the family Marcgraviaceae and from plants of the family Platanaceae. The disclosure also provides methods and uses of plant preparations for treating anxiety, st...  
WO/2014/073450
The present invention addresses the problem of providing a drunkenness-relieving agent which can relieve the severity of a badly or heavily drunk state in heavy alcohol use. The means for solving the problem is the use of an insoluble co...  
WO/2014/074795
The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working densi...  
WO/2014/072261
The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders.  
WO/2014/072881
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention...  
WO/2014/071449
The present disclosure teaches generally neuroprotection and in particular the use of non-hormonal neuroactive steroids to ameliorate inflammation of the central nervous system (CNS). More specifically, the present claims define methods ...  
WO/2014/072957
Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5 and m are as described herein, as a modulator of nicotinic acetylcholine receptors particularly α7 subtype, its tautomeric forms, its stereoisomers, its pharmaceutically...  
WO/2014/073946
The invention relates to the use of betanidine and its derivatives, betalains and their derivatives, betalamic acid and its derivatives, including the spatial configurations thereof, for the production of a drug for the treatment, preven...  
WO/2014/074976
Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, de...  
WO/2014/072498
The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carboni trile derivatives having pharmacological activity formula (I) to processes of preparation of such compounds, to pharmaceutical compositions com...  
WO/2014/074592
The instant invention relates to seaweed extract compositions, processes for isolation, isolated active agents, and methods of treating disease, disorders and conditions in a subject, including, reactive oxygen species (ROS)- mediated di...  
WO/2014/071371
Disclosed herein are cocrystals of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, which is a prodrug of methyl hydrogen fumarate  
WO/2014/069667
An objection of the present invention is to provide an agent for preventing or improving decline in brain function such as decreased perception ability, decreased memory learning ability, decreased thinking ability, decreased concentrati...  
WO/2014/068988
The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which v...  
WO/2014/071134
In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embod...  
WO/2014/068372
The present invention relates to a pharmaceutical composition of tapentadol for parenteral administration which provides prolonged release of tapentadol. Present invention also relates to the process of preparation of pharmaceutical comp...  
WO/2014/071042
The present invention provides, inter alia, methods for identifying a candidate agent that may be effective to treat or ameliorate an effect of a neurodegenerative disease in a subject. These methods include: (a) contacting a wildtype ne...  
WO/2014/069626
Provided is a method for producing a compound represented by formula (I) (wherein R1 and R2 may be the same or different and each represents a hydrogen atom or the like, and Z represents an optionally substituted aryl group or the like) ...  
WO/2014/070038
The invention relates to the pharmaceutical industry and the field of medicine and can be used in the creation and administration of solid dosage forms having neuroprotective, antiamnesic, antioxidant, antihypoxic and anti-ischemic activ...  
WO/2014/071219
The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfec...  
WO/2014/067281
Disclosed is a tapentadol hydrochloride crystalline form C having high stability and having characteristic peaks at 14.627 (100%), 15.476 (20.7%), 16.710 (33.7%), 18.999 (48.3%), 20.479 (80.7%), 21.790 (27.9%), 25.110 (35.2%), 25.911 (36...  
WO/2014/071044
The invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R', R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are ...  
WO/2014/067038
Disclosed are target points for treating human ADSL deficiency, the target points comprising PAICS gene, mRNA of PAICS gene or PAICS protein. Use of PAICS gene, mRNA of PAICS gene or PAICS protein for treating human ADSL deficiency is al...  
WO/2014/068499
This invention relates to a method of increasing a feeling of a) energy or b) cognitive functions, selected from the group consisting of: sustained attention, faster reaction times, and information processing; or c) quality of sleep; or ...  
WO/2014/067505
The invention relates to peptides which bind to amino-terminal truncated pEAβ3-42, the free glutamic acid group of which lies in position 3 or 11 in the form of cyclized pyroglutamate. Four oligopeptides were identified using mirror ima...  
WO/2014/069666
An objection of the present invention is to provide an agent for preventing or improving decline in brain function such as decreased perception ability, decreased memory learning ability, decreased thinking ability, decreased concentrati...  
WO/2014/071194  
WO/2014/070745
Solid forms of certain opioid agonists are provided herein. Methods of preparing the solid forms, methods of using the solid forms, and pharmaceutical compositions comprising the solid forms are also provided herein.  
WO/2014/069434
[Problem] To provide a novel thiazolidinone derivative. [Solution] A thiazolidinone derivative or a pharmaceutically acceptable salt thereof represented by formula (I) or (II). (I) (II)  
WO/2014/068171
Compounds of formula I or formula II, wherein Q1Q3 and R1-R5 are as defined in the claims, exhibit CytC derived peroxidase inhibiting activity and are thus useful as CytC derived peroxidase inhibiting agents.  
WO/2014/068327
The present invention relates to the use of agents (including heparin derivatives) for the prevention and/or treatment of CNS damage.  
WO/2014/071157
The invention provides compositions and in vivo, ex vivo and in vitro methods for trans-differentiation of or re-programming mammalian cells to functional neurons. In particular, the invention provides methods for engineering non-neurona...  
WO/2014/071005
Described herein are compositions and methods for treating or preventing ischemic injury. In particular, the methods and compositions relate to the use of a neuroprotective steroid, such as a progestogen, such as progesterone or allopreg...  

Matches 401 - 450 out of 46,375